McMillin et al. describe a drug screening platform that takes into account the tumor microenvironment, in particular tumor-stromal interactions, enabling the screening of the antitumor activity of candidate anticancer agents in the context of such interactions. The in vitro tumor cell–specific bioluminescence imaging assay is both high throughput and scalable.
- Douglas W McMillin
- Jake Delmore
- Constantine S Mitsiades
